CJC-1295 With DAC – 5mg

CJC-1295 with DAC is a modified analogue of growth hormone-releasing hormone (GHRH) developed for research into longer-duration peptide signalling.

The Drug Affinity Complex, or DAC, is an attached chemical modification that enables interaction with albumin. In research models, this changes the peptide’s stability and persistence compared with shorter-duration GHRH-related peptides.

Pronoia supplies CJC-1295 with DAC as a 5mg lyophilised research material for controlled laboratory studies of peptide signalling, stability and peptide–protein interactions.

Product: CJC-1295 with DAC

Specification: 5mg

Material class: Modified GHRH analogue

Modification: Drug Affinity Complex (DAC)

Form: Lyophilised solid

Minimum purity standard: ≥98%

Batch traceability: Maintained

Pronoia maintains batch traceability for CJC-1295 with DAC and retains supporting analytical documentation for the supplied research material.

Independent analytical testing supports product quality assessment, with batch-specific documentation used to record identity, purity and consistency.

Where a particular testing method or analytical result is reported for an individual batch, the corresponding Certificate of Analysis should be treated as the authoritative reference.

Certificate of Analysis (COA) and Safety Data Sheet (SDS) documentation are available to support laboratory records and material assessment.

CJC-1295 with DAC has been investigated as a modified GHRH analogue in research examining prolonged peptide activity, receptor signalling and peptide stability.

Research areas associated with CJC-1295 with DAC include:

• Extended-duration GHRH-receptor signalling
• Peptide stability and persistence studies
• Albumin-binding and peptide–protein interaction research
• Endocrine signalling models
• Structure–function studies of modified GHRH analogues
• Comparison of longer- and shorter-duration peptide designs

The DAC modification is particularly important in this research context because albumin association allows investigators to study how chemical modification can alter the duration and behaviour of a peptide within an experimental system.

These research contexts describe experimental investigation only and do not imply suitability for human or veterinary use.

CJC-1295 with DAC is supplied in lyophilised form to support stability during storage and laboratory handling.

The product should be maintained under the temperature-controlled conditions specified by Pronoia and the applicable batch documentation, protected from unnecessary heat, moisture and repeated environmental exposure.

Researchers should follow appropriate laboratory procedures when preparing or handling the material and use validated protocols appropriate to their experimental requirements.

Where batch-specific storage instructions are supplied, those instructions should take precedence.

CJC-1295 with DAC is supplied through Pronoia’s tracked UK delivery service using its established research-product fulfilment process.

Batch traceability is maintained, with Certificate of Analysis (COA) and Safety Data Sheet (SDS) documentation available to support laboratory records and material assessment.

Current dispatch availability and applicable delivery conditions are displayed directly on the product page and remain subject to Pronoia’s delivery terms.

CJC-1295 with DAC supplied by Pronoia Bio is intended strictly for controlled laboratory research and experimental use.

It is not supplied for human or veterinary use and should not be treated as a medicine or consumer healthcare product.

Purchasers are responsible for ensuring that the material is used appropriately within their research environment and in accordance with applicable requirements.